stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
2,025.68 | 1,908.08 | 3,937.97 | 3,651.39 |
Total current assets |
2,075.04 | 1,967.91 | 4,028.34 | 3,976.70 | |
Property, Plant, Equpment (Net) |
33.19 | 31.48 | 34.61 | 34.63 | |
Long-Term Investments |
24.15 | 34.71 | 42.45 | 65.65 | |
Goodwill and Intangible Assets (Total) |
70.41 | 70.41 | 70.41 | 70.08 | |
Long-term assets (Other) |
19.64 | 19.34 | 19.62 | — | |
Total non-current assets |
279.47 | 285.82 | 294.93 | 326.82 | |
Total Assets |
2,354.51 | 2,253.74 | 4,323.27 | 4,303.51 | |
Accounts Payable |
64.62 | 80.54 | 88.42 | 100.66 | |
Accrued Expenses |
209.34 | 192.45 | 248.89 | — | |
Total current liabilities |
290.42 | 289.60 | 354.06 | 475.67 | |
Long Term Debt (Total) |
268.45 | 280.64 | 1,035.98 | — | |
Long Term Tax Liability (Deferred) |
2.35 | 2.35 | 2.35 | — | |
Non-current Liabilities (Other) |
19.75 | 41.21 | 186.90 | — | |
Total non-current liabilities |
432.79 | 464.22 | 1,362.97 | 1,426.34 | |
Total liabilities |
723.21 | 753.82 | 1,717.03 | 1,902.01 | |
Additional Paid In Capital |
4,497.14 | 4,823.44 | 6,579.46 | 6,790.90 | |
Common Stock (Net) |
0.02 | 0.02 | 0.02 | 0.02 | |
Retained Earnings |
(2,869.10) | (3,322.92) | (3,967.29) | (4,374.75) | |
Common Equity (Total) |
1,631.30 | 1,499.92 | 2,606.24 | 2,401.50 | |
Shareholders Equity (Total) |
1,631.30 | 1,499.92 | 2,606.24 | 2,401.50 | |
Shareholders Equity and Liabilities (Total) |
2,354.51 | 2,253.74 | 4,323.27 | 4,303.51 | |
Shares (Common) |
197.00 | 200.18 | 214.24 | 216.25 | |
Shareholders Equity (Tangible) |
1,560.89 | 1,429.51 | 2,535.83 | 2,331.42 | |
Net Debt |
(1,757.23) | (1,627.44) | (2,901.99) | (3,651.38) | |
Total Debt |
268.45 | 280.64 | 1,035.98 | — |